Illumina, Inc. $ILMN Stock: Focus Advisor Solutions LLC Boosts Stake

Focus Advisor Solutions LLC boosted its position in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 68.8% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 25,224 shares of the life sciences company’s stock after acquiring an additional 10,278 shares during the period. Focus Advisor Solutions LLC’s holdings in Illumina were worth $6,904,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in shares of Illumina in the second quarter valued at approximately $3,374,423,000. Primecap Management Co. CA bought a new position in Illumina in the 2nd quarter worth approximately $617,981,000. Ninety One UK Ltd boosted its holdings in Illumina by 37,920.0% in the 3rd quarter. Ninety One UK Ltd now owns 1,359,974 shares of the life sciences company’s stock worth $372,198,000 after buying an additional 1,356,397 shares during the period. Jupiter Topco LLC purchased a new position in Illumina in the 2nd quarter valued at approximately $358,652,000. Finally, Wellington Management Group LLP grew its stake in Illumina by 190.1% in the 2nd quarter. Wellington Management Group LLP now owns 1,812,928 shares of the life sciences company’s stock valued at $318,767,000 after buying an additional 1,188,004 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on ILMN shares. TD Cowen lifted their price target on Illumina from $210.00 to $270.00 and gave the company a “hold” rating in a research report on Tuesday, October 13th. Guggenheim increased their price objective on Illumina from $226.00 to $305.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Leerink Partners raised their target price on Illumina from $220.00 to $300.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 29th. Royal Bank Of Canada lifted their target price on Illumina from $230.00 to $310.00 and gave the company an “outperform” rating in a report on Monday, October 5th. Finally, Sanford C. Bernstein reiterated a “market perform” rating and set a $215.00 price target on shares of Illumina in a research report on Friday, July 31st. Nine analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $243.72.

Check Out Our Latest Research Report on Illumina

Insider Buying and Selling

In other news, Director Keith A. Meister sold 98,833 shares of Illumina stock in a transaction on Wednesday, November 11th. The shares were sold at an average price of $216.87, for a total transaction of $21,433,912.71. Following the completion of the sale, the director directly owned 208,826 shares of the company’s stock, valued at approximately $45,288,094.62. The trade was a 32.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Scott D. Ericksen sold 267 shares of the company’s stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $217.76, for a total transaction of $58,141.92. Following the completion of the transaction, the chief accounting officer owned 14,029 shares of the company’s stock, valued at $3,054,955.04. This trade represents a 1.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,201,292 shares of company stock worth $270,151,290 over the last ninety days. 2.90% of the stock is currently owned by insiders.

Illumina News Summary

Investors following ILMN have been watching these news items:

  • Positive Sentiment: A proposed federal bill would require Medicaid coverage for whole-genome and whole-exome sequencing for certain children. If enacted, broader coverage could support more genetic testing and demand for Illumina’s sequencing systems; the bill is not yet law. Genomic Answers for Children’s Health Act of 2026
  • Neutral Sentiment: Bernstein has a Hold rating on ILMN, indicating a more measured view of near-term upside. Illumina Gets a Hold from Bernstein
  • Neutral Sentiment: Recent coverage attributes Illumina’s strong year-over-year performance to clinical sequencing demand, NovaSeq X adoption, and expansion into multiomics and AI. These longer-term drivers may support investor sentiment, but are not a new quarterly update. What’s Fueling Illumina’s Rally?

Illumina Price Performance

Illumina stock opened at $200.65 on Friday. Illumina, Inc. has a 52 week low of $112.65 and a 52 week high of $309.35. The business has a 50-day simple moving average of $248.54 and a 200 day simple moving average of $180.77. The company has a quick ratio of 2.05, a current ratio of 2.63 and a debt-to-equity ratio of 0.57. The stock has a market cap of $30.34 billion, a price-to-earnings ratio of 40.00, a PEG ratio of 2.85 and a beta of 1.46.

Illumina (NASDAQ:ILMN – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.36 by $0.26. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The firm had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.15 billion. During the same quarter last year, the company posted $1.34 EPS. The company’s revenue for the quarter was up 4.2% on a year-over-year basis. On average, research analysts forecast that Illumina, Inc. will post 5.43 earnings per share for the current fiscal year.

Illumina Company Profile

(Free Report)

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.

Featured Stories

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.